Ross Parfitt

Genetic variation of cisplatin-induced ototoxicity in non-cranial-irradiated pediatric patients using a candidate gene approach: The International PanCareLIFE Study

Eva Clemens, Linda Broer, Thorsten Langer et al. · The Pharmacogenomics Journal · 2019 · 50 citations · Full text

Radiation Medicine, Radiation Effect, Cisplatin-induced Ototoxicity +6

Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study

Thorsten Langer, Eva Clemens, Linda Broer et al. · European Journal of Cancer · 2020 · 42 citations · Full text

Cancer Risk, Medicine, Childhood Cancer Patients +6

TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study

Annelot J. M. Meijer, Franciscus A. Diepstraten, Thorsten Langer et al. · npj Precision Oncology · 2021 · 21 citations · Full text

Impact of radiation technique, radiation fraction dose, and total cisplatin dose on hearing

Sergiu Scobioala, Ross Parfitt, Peter Matulat et al. · Strahlentherapie und Onkologie · 2017 · 20 citations

Radiation Medicine, Radiation Therapy, Total Cisplatin Dose +15

Severity of hearing loss after platinum chemotherapy in childhood cancer survivors

Sven Strebel, Luzius Mader, Tomáš Sláma et al. · Pediatric Blood & Cancer · 2022 · 19 citations · Full text